Celldex Therapeutics Inc.

Chronic urticaria disorders

Celldex Therapeutics Inc. focuses on chronic spontaneous urticaria and chronic inducible urticaria, including cold-induced urticaria and symptomatic dermographism. Its clinical work in this area centers on persistent wheal-and-itch disease burden and provocation-test outcomes.

  • Chronic spontaneous urticaria
  • Chronic inducible urticaria
  • Cold-induced urticaria
  • Symptomatic dermographism

The sponsor’s studies in urticaria span multiple active sites across several countries, reflecting a broad interest in mast cell–driven skin disease and symptom control.

Pruritic inflammatory skin disease

Another key area is prurigo nodularis, a chronic inflammatory dermatologic condition marked by intense itch and nodular skin lesions. The research emphasis is on itch reduction and disease activity in patients with persistent pruritic symptoms.

  • Prurigo nodularis
  • Itch severity
  • Chronic skin inflammation

This area highlights interest in dermatology programs targeting severe itch-associated disease and long-term symptom burden.

Eosinophilic gastrointestinal disease

Celldex Therapeutics Inc. also funds research in eosinophilic esophagitis, with attention to esophageal inflammation and mast cell involvement in the upper gastrointestinal tract. The therapeutic focus extends beyond skin disease into immune-mediated esophageal pathology.

  • Eosinophilic esophagitis
  • Esophageal inflammation
  • Mast cell infiltration

This work places the sponsor within the field of allergic and eosinophilic disorders affecting gastrointestinal function.

Immunology and mast cell biology

Across its clinical portfolio, the sponsor shows a consistent interest in disorders linked to mast cell activation, histamine-mediated symptoms, and immune-driven itching or swelling. These themes connect its dermatology and gastrointestinal programs.

  • Mast cell activation
  • Histamine-mediated symptoms
  • Immune-mediated inflammation

The research landscape is centered on conditions where immune dysregulation produces chronic symptom burden and tissue inflammation.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Lithuania Poland Spain
  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark France +10
  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +5
  • Study on the Effects of Barzolvolimab for Patients with Prurigo Nodularis

    Not recruiting

    2 1
    Investigated drugs:
    Croatia Germany Poland Spain
  • Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

    Not recruiting

    2 1 1
    Investigated drugs:
    Bulgaria Germany Hungary Latvia Lithuania Poland +1
  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Croatia Germany Hungary Italy Lithuania +4